Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:35:19.693Z.
Calculation as of: 2026-10-06T13:35:19.693Z.
Quote observation: 2026-10-06T13:33:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd475241593d5c58f7737f650220a879a7f67ee05652ed27eb0102460b642cb0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$87.74M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.52M
Price/FCF Ratio
21.00
TTM Avg
49.21
3Y Avg
51.81
5Y Avg
51.81
Market Cap
$89.36M
Price/FCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$84.61M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.40M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $87.74M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $88.17M | 4.07 | 5.32 | 4.50 | 8.18 |
| ImmuCell Corporation (ICCC)vs › | $88.52M | 21.00 | 49.21 | 51.81 | 51.81 |
| Conexeu Sciences Inc. (CNXU)vs › | $89.11M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $89.15M | N/A | 24.77 | 24.77 | 24.77 |
| Cardiff Oncology, Inc. (CRDF)vs › | $89.36M | N/A | 17.74 | 16.00 | 17.53 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.61M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.55M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.40M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.51M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute